Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-8264 for Prevention of Cardiac Surgery-Associated Acute Kidney Injury
2024-513125-23-00Phase 2Completed
- Sponsor
- Genentech
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF) and chronic kidney disease (CKD) comparing GDC-8264 with Placebo (2 arms). Primary endpoint: Major Adverse Kidney Events at 90 days (MAKE90). Started Feb 2025; status: completed.
02
Drugs
GDC-8264
03
Conditions
acute kidney failure (AKF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-513125-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513125-23-00.